Periodic Reporting for period 1 - CARE-IN-HEALTH (CArdiovascularREsolution of INflammation to promote HEALTH)
Período documentado: 2023-01-01 hasta 2024-06-30
CARE-IN-HEALTH tackles the major public health issue of cardiovascular diseases (CVD) that affects the lives of over 49 million people annually in Europe and incur a €200 billion economic burden. The overarching objective of CARE-IN-HEALTH is to identify the mechanisms involved in the resolution of the chronic lipid-driven/-regulated vascular inflammation in order to develop and test, in a real-life setting, tools for use in health care and by citizens to stay healthy by an adequate resolution of the chronic inflammation behind the health-to-CVD transition.
The WP1 aims to establish lipidomic profiling of the health-to-CVD transition to distinguish between resolving and non-resolving inflammation.
During the first 18 months the focus has been on methodology development for full lipidomic profiling, and the application of the methods in selected samples from the CARE-IN-HEALTH cohorts.
The WP2 aims to explore lipid immunology with a focus on understanding how lipid mediators influence immune responses. The objectives include providing functional, molecular, immune-metabolic, and immuno-thrombosis data to the CARE-IN-HEALTH atlas, aiding in the identification and validation of targets for diagnosing, preventing, and treating the health-to-CVD transition.
During the first 18 months, we focused on developing and standardizing methodologies for studying lipid-mediated immune responses. Significant accomplishments include standardizing cell culture conditions, identifying key immunometabolic pathways regulating immune and vascular responses, and creating bioinformatic platforms for EV dataset analysis.
The WP3 aims to establish the associations of chronic non-resolving inflammation with the full continuum of the health-to-CVD transition, in three cohorts monitoring i) prevalent, ii) subclinical, iii) incident CVD.
During the first 18 months collection of available data on clinical characteristics, genetic variations, lipid exposure by dietary intake, and biomarkers from 3 large cohorts has allowed initiation of epidemiological analyses for the health-to-CVD transition outcome measures.
The WP4 aims to retro- and prospectively determine the impact of dietary lipid interventions on systemic and local lipid-driven/regulated inflammation on the health-to-CVD transition and to provide proof-of-concept for the care-in-health applications
During the first 18 months the retrospective analysis of GISSI Prevenzione and GISSI-HF (n=20000) has started and it will allow to explore the effects of n-3 polyunsaturated Fatty Acids (PUFA) 1 g/day on circulatory measures of immunology and lipidome. Two smaller proof-of-concept studies, POMEGA-2 and RESOLVIN will extend and complement information derived from the GISSI studies.
The WP5 aims the integration, curation, harmonization and standardization of existent and produced data resources to be used for machine learning approaches to identify personalized factors predicting resolving vs. non-resolving inflammation, the critical lipid mediators, and how to predict different stages of the health-to-CVD transition outcome measures.
During the first 18 months we began integrating and harmonizing data into the CARE-IN-HEALTH Atlas, laying the groundwork for the development of the CARE-IN-HEALTH MCDSS.
The WP6 aims to develop and validate a point-of-care cardiovascular disease (CADIS) diagnostic tool (biosensor) prototype for non-technical users/ healthcare professionals to identify and prevent the health-to-CVD transition.
During the first 18 months I3S has developed the AptaShield sensor technology for high-throughput biomarker quantification, applicable to both optical and electrochemical detection. Additionally, I3S has implemented an advanced quality control system for the fabrication and functionalization of electrochemical sensing devices.
The WP7, 8 and 9 aim to ensure the effective communication and dissemination of project results, maximize the exploitation of research outcomes, provide robust project management and governance, and uphold the highest ethical standards.
During the first 18 months these WPs have facilitated streamlined administrative processes and smooth communication both within and outside the consortium. Additionally, it has been initiated the development of a strategic plan has been initiated to broaden impact of the project findings.
During the first 18 months the focus has been on methodology development for full lipidomic profiling, and the application of the methods in selected samples from the CARE-IN-HEALTH cohorts.
The WP2 aims to explore lipid immunology with a focus on understanding how lipid mediators influence immune responses. The objectives include providing functional, molecular, immune-metabolic, and immuno-thrombosis data to the CARE-IN-HEALTH atlas, aiding in the identification and validation of targets for diagnosing, preventing, and treating the health-to-CVD transition.
During the first 18 months, we focused on developing and standardizing methodologies for studying lipid-mediated immune responses. Significant accomplishments include standardizing cell culture conditions, identifying key immunometabolic pathways regulating immune and vascular responses, and creating bioinformatic platforms for EV dataset analysis.
The WP3 aims to establish the associations of chronic non-resolving inflammation with the full continuum of the health-to-CVD transition, in three cohorts monitoring i) prevalent, ii) subclinical, iii) incident CVD.
During the first 18 months collection of available data on clinical characteristics, genetic variations, lipid exposure by dietary intake, and biomarkers from 3 large cohorts has allowed initiation of epidemiological analyses for the health-to-CVD transition outcome measures.
The WP4 aims to retro- and prospectively determine the impact of dietary lipid interventions on systemic and local lipid-driven/regulated inflammation on the health-to-CVD transition and to provide proof-of-concept for the care-in-health applications
During the first 18 months the retrospective analysis of GISSI Prevenzione and GISSI-HF (n=20000) has started and it will allow to explore the effects of n-3 polyunsaturated Fatty Acids (PUFA) 1 g/day on circulatory measures of immunology and lipidome. Two smaller proof-of-concept studies, POMEGA-2 and RESOLVIN will extend and complement information derived from the GISSI studies.
The WP5 aims the integration, curation, harmonization and standardization of existent and produced data resources to be used for machine learning approaches to identify personalized factors predicting resolving vs. non-resolving inflammation, the critical lipid mediators, and how to predict different stages of the health-to-CVD transition outcome measures.
During the first 18 months we began integrating and harmonizing data into the CARE-IN-HEALTH Atlas, laying the groundwork for the development of the CARE-IN-HEALTH MCDSS.
The WP6 aims to develop and validate a point-of-care cardiovascular disease (CADIS) diagnostic tool (biosensor) prototype for non-technical users/ healthcare professionals to identify and prevent the health-to-CVD transition.
During the first 18 months I3S has developed the AptaShield sensor technology for high-throughput biomarker quantification, applicable to both optical and electrochemical detection. Additionally, I3S has implemented an advanced quality control system for the fabrication and functionalization of electrochemical sensing devices.
The WP7, 8 and 9 aim to ensure the effective communication and dissemination of project results, maximize the exploitation of research outcomes, provide robust project management and governance, and uphold the highest ethical standards.
During the first 18 months these WPs have facilitated streamlined administrative processes and smooth communication both within and outside the consortium. Additionally, it has been initiated the development of a strategic plan has been initiated to broaden impact of the project findings.
CARE-IN-HEALTH is pushing the boundaries of CVD prevention by moving beyond outdated dietary guidelines. The project aims to create algorithms for personalized lifestyle modifications and monitoring, helping to optimize individual and public health outcomes and sustainability.
The results obtained in the first 18 months of the project go in the direction of a major advancement towards promoting resolution-health by balancing inflammation resolution without causing immunosuppression. Unlike traditional anti-inflammatory concepts in CVD prevention, the results obtained within CARE-IN-HEALTH provide indications on how to maintain immune function while reducing inflammation. These results provide insights into the key challenge in current CVD prevention strategies, in particular the intricate lipid-inflammation interaction.
Key Needs for Further Uptake and Success:
1. Integration with Clinical Practice: Incorporate personalized tools into healthcare systems.
2. Awareness: Educate healthcare professionals and the public on new approaches.
3. Regulatory Support: Engage with policymakers for approvals and alignment.
4. Access to Markets and Finance: Secure funding and establish pathways for market entry to scale solutions.
5. Commercialization: Develop strategies to bring innovations to market, including partnerships with industry.
6. IPR Support: Ensure robust intellectual property protection to safeguard innovations.
The results obtained in the first 18 months of the project go in the direction of a major advancement towards promoting resolution-health by balancing inflammation resolution without causing immunosuppression. Unlike traditional anti-inflammatory concepts in CVD prevention, the results obtained within CARE-IN-HEALTH provide indications on how to maintain immune function while reducing inflammation. These results provide insights into the key challenge in current CVD prevention strategies, in particular the intricate lipid-inflammation interaction.
Key Needs for Further Uptake and Success:
1. Integration with Clinical Practice: Incorporate personalized tools into healthcare systems.
2. Awareness: Educate healthcare professionals and the public on new approaches.
3. Regulatory Support: Engage with policymakers for approvals and alignment.
4. Access to Markets and Finance: Secure funding and establish pathways for market entry to scale solutions.
5. Commercialization: Develop strategies to bring innovations to market, including partnerships with industry.
6. IPR Support: Ensure robust intellectual property protection to safeguard innovations.